IRulya Therapeutics Inc. (IRLA) Key Metrics
IRLA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $32.6M
- Enterprise value
- −$86.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.2
- EV / EBITDA
- 1.4
- Dividend yield
- —
- Beta
- 1.33
IRLA key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIRLA valuation Price multiples at each fiscal year-end price.
IRLA returns How much profit the business earns on the capital it uses.
IRLA per-share figures Results divided by the shares outstanding at year-end.
IRLA financial health Debt, liquidity and how easily interest is covered.
IRLA valuation history
IRLA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IRLA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IRLA price vs earnings per share
IRLA key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $167.8M | $80.9M | — | — |
| Enterprise value | $168.5M | $54.9M | — | — |
| Price / book | — | 2.7 | — | — |
| Earnings yield | −50.0% | −70.2% | — | — |
| Free cash flow yield | −24.9% | −39.8% | — | — |
| Share price at fiscal year-end | $670.00 | $374.00 | $210.00 | $127.40 |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | — | — |
| Earnings per share | −$335.27 | −$262.71 | — | — |
| Operating cash flow per share | −$165.38 | −$147.49 | — | — |
| Free cash flow per share | −$166.78 | −$148.68 | — | — |
| Cash per share | $70.87 | $188.54 | — | — |
| Book value per share | −$142.58 | $139.36 | — | — |
| Tangible book value per share | −$413.33 | −$138.22 | — | — |
| Capex per share | $1.41 | $1.19 | — | — |
| Debt per share | $73.74 | $68.47 | — | — |
| Shares outstanding | 250K | 216K | — | — |
| Change in shares outstanding | +15.8% | — | — | — |
| Returns & profitability | ||||
| Return on equity (ROE) | — | −98.6% | −33.8% | −51.4% |
| Return on invested capital (ROIC) | — | −323.1% | −157.6% | −378.2% |
| Return on assets (ROA) | −80.7% | −38.6% | −22.1% | −49.7% |
| Return on tangible assets | −326.7% | −104.4% | −31.7% | −52.7% |
| Financial health | ||||
| Total debt | $18.5M | $14.8M | $13.8M | $453,000 |
| Cash & short-term investments | $17.8M | $40.8M | $75.1M | $90.2M |
| Net debt | $719,000 | −$26.0M | −$61.2M | −$89.7M |
| Debt / equity | — | 0.49 | 0.16 | 0.00 |
| Debt / assets | 0.20 | 0.13 | 0.08 | 0.00 |
| Current ratio | 0.53 | 6.05 | 8.09 | 30.55 |
| Quick ratio | 0.53 | 6.05 | 8.09 | 30.55 |
| Interest coverage | — | — | — | -91.6 |
| Working capital | −$20.3M | $36.8M | $67.9M | $90.7M |
| Invested capital | −$35.0M | $4.2M | $23.8M | $10.9M |
| Tangible asset value | −$103.5M | −$29.9M | $3.8M | $94.7M |
| Net current asset value | −$106.3M | −$40.3M | −$17.7M | $90.4M |
| Graham net-net per share | −$434.23 | −$198.26 | — | — |
| Capital allocation | ||||
| Capex / depreciation | 2.48 | 1.38 | 0.50 | 0.65 |
| Efficiency | ||||
| Days payables outstanding | 6,588.0 | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | — |
| Payables turnover | 0.06 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $2.3M | $937,500 | $993,000 | — |
| Average payables | $2.6M | $2.5M | $1.3M | $570,000 |
| Intangibles / total assets | 72.5% | 52.5% | 45.1% | 5.7% |
Computed from IRLA's annual financial statements (latest annual report filed April 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IRLA valuation and financial ratios
It ended the year with $18.5 million of debt and $17.8 million in cash and short-term investments, net debt of $0.7 million.
See the IRLA income statement, the IRLA chart for price history, or the IRLA stock overview for the latest quote and news.
IRLA key metrics FAQ
How much debt does IRulya Therapeutics have?
IRulya Therapeutics had total debt of $18.5 million at the end of fiscal 2025.
What is IRulya Therapeutics's free cash flow yield?
IRulya Therapeutics generated -$41.8 million of free cash flow in fiscal 2025, a free cash flow yield of −24.9% on its market value at year-end ($167.8 million).
What is IRulya Therapeutics's current ratio?
IRulya Therapeutics's current ratio was 0.53 at the end of fiscal 2025: current assets were 0.53 times current liabilities.